Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 13/20 | 0.47 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.45 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 8/20 | 0.43 |
| ▸ | LCK | P06239 | 6/20 | 0.43 |
| ▸ | ITK | Q08881 | 5/20 | 0.43 |
| ▸ | VCP | P55072 | 3/20 | 0.43 |
| ▸ | PSMC4 | P43686 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617847 | 0.91 | VCP (0.43) | BTKNUDT14NUDT5EGFRLCK | |
| SCHEMBL14617845 | 0.88 | HTT (0.42) | BTKNUDT14NUDT5VCPPSMC4 | |
| SCHEMBL14693504 | 0.80 | ABL1 (0.38) | EGFRLCKSRCPIK3CDABL1 | |
| SCHEMBL31113537 | 0.76 | BTK (0.53) | BTKNUDT14NUDT5EGFRLCK | |
| SCHEMBL30718278 | 0.75 | NUDT14 (0.55) | BTKNUDT14NUDT5EGFRLCK | |
| SCHEMBL22720780 | 0.75 | NUDT14 (0.55) | BTKNUDT14NUDT5EGFRLCK | |
| SCHEMBL13012718 | 0.73 | BTK (0.54) | BTKLCKJAK3KDR | |
| SCHEMBL25068862 | 0.72 | NUDT14 (0.68) | BTKNUDT14NUDT5EGFRLCK | |
| SCHEMBL25068860 | 0.72 | NUDT14 (0.64) | BTKNUDT14NUDT5EGFRLCK | |
| SCHEMBL15087023 | 0.72 | GPR119 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862722-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2015-11-19 | — | — | US | disclosed |
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2013010136-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885NUDT14 1389/4885NUDT5 1617/4885 |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885NUDT14 1389/4885NUDT5 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.